Following the signature of a preliminary agreement last November, Actavis Group and ASKA Pharmaceutical have now formally signed an agreement establishing a joint company: Actavis ASKA K.K.
The joint company will enter the Japanese generic pharmaceutical market in April 2009. ASKA will hold 55% of shares in the joint venture; Actavis 45%
The details can be read here.
No comments:
Post a Comment